Drug Discovery@nature.com 8 February 2013

TABLE OF CONTENTS 8 February 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement We've got something to share with you Access the latest scientific news and research when and where you want it. Download the latest issues to browse at your convenience, zoom in on figures and images, save your searches and synchronize your bookmarks across devices. Tap in to find out more   News Top Amgen punts on deCODE's genetics know-how doi:10.1038/nbt0213-87 Amgen's acquisition of deCODE Genetics provides validation that large biopharma firms are increasingly integrating human genetics research into their discovery and clinical programs. Full Text BioTime acquires Geron's stem cell program doi:10.1038/nbt0213-94a Geron's stem cell assets were given a new lease in early January when BioTime of Alameda, California, signed a definitive agreement to take control of the human embryonic stem cell program. Full Text Startups, inventors cheer European unified patent doi:10.1038/nbt0213-92c The European Parliament has voted positively on proposals to establish a unitary patent for Europe, which is to be introduced in 2014. Full Text First novel anti-tuberculosis drug in 40 years doi:10.1038/nbt0213-89 The FDA has approved a new drug to treat tuberculosis. It is the first anti-mycobacterial compound with a novel mechanism of action in 40 years. Full Text Analysis Top CRISPR genome editing doi:10.1038/scibx.2013.77 Five separate research teams have developed a Cas9 endonuclease–based method for sequence-specific genome modification. Although the approach is technically more straightforward than existing methods, its specificity has yet to be fully determined. Full Text Smoking cessation drugs market doi:10.1038/nrd3914 This analysis looks at smoking cessation therapies currently in development, including the novel approach of vaccinating smokers against nicotine. Full Text Research Highlights Top Antibacterial drugs: New antibiotics on the horizon? doi:10.1038/nrd3940 Two recent papers report novel strategies for combating the prevalent bacterial pathogen Staphylococcus aureus. Full Text Neurodegenerative disease: Targeting pre-existing plaques in AD doi:10.1038/nrd3939 Researchers have developed a plaque-specific monoclonal antibody that can clear existing plaques without the side effects seen with other anti-amyloid-β therapeutics in development. Full Text Anticancer drugs: Assault on MALT1 doi:10.1038/nrd3942 Two new studies have identified small-molecule inhibitors of MALT1 that show anticancer activity in vitro and in vivo. Full Text Research & Reviews Top Targeting eosinophils in allergy, inflammation and beyond doi:10.1038/nrd3838 The authors describe recent advances in the development of the first generation of therapies that target eosinophils, as well as emerging strategies. Full Text Advances in targeting cell surface signalling molecules for immune modulation doi:10.1038/nrd3877 This review discusses immunomodulatory signalling pathways that provide targets for therapeutic intervention and the current state of drug development in the field. Full Text Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production doi:10.1038/nbt.2458 Researchers present a systems-based method to tune ROS production in bacteria and demonstrate that increased microbial ROS production can potentiate killing by oxidants and antibiotics. Full Text Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance doi:10.1038/nm.3056 As expression of this transcriptional regulator is elevated in fat from obese humans, TRIP-Br2 might be a new therapeutic target against insulin resistance and hyperlipidemia. Full Text Drug Discovery JOBS of the week Director, Vaccine Research Center National Institute of Allergey and Infectious Diseases/NIH Director, Clinical Research Program National Institute of Environmental Health Sciences Senior Analytical Development Chemist (GMP) Hudson Shribman Scientific Recruitment Ltd Chemist Forschungszentrum Jülich - Research Center Jülich Carbohydrate chemist / antitumoral synthetic vaccines University of Grenoble, France More Science jobs from Drug Discovery EVENT Tumor Imaging in Cancer Drug Development 04.30.13 Boston, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.